Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 03 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Mirabegron Extended-Release Tablets. The tablets will be manufactured at Zydus's facility in Ahmedabad, India. This marks a significant milestone as Zydus was among the first applicants to submit a complete application for this drug.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange about press release dated 03-Oct-2022 titled Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets 3.10.22

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases